GDF-15对GRACE风险校正能提高对非ST段压低急性冠脉综合征的预测价值

2011-12-29 MedSci MedSci原创

MedSci评论:  GDF-15是一种新的评价指标, 近年来人们一直在探寻新的敏感的和特异性评价指标。传统评价冠脉事件的指标如LDH,CK-MB,Troponin I等等,近年来又发现pro-BNP,MMP-2,6,9,TIMP-2,PⅢNP,CD40L等等,如果将这些指标间相互作用,以及用于心血管事件的预测,具有相当重要的意义,如果在临床研究中注意收集这些信息,有助于形成新的临

MedSci评论:
 GDF-15是一种新的评价指标, 近年来人们一直在探寻新的敏感的和特异性评价指标。传统评价冠脉事件的指标如LDH,CK-MB,Troponin I等等,近年来又发现pro-BNP,MMP-2,6,9,TIMP-2,PⅢNP,CD40L等等,如果将这些指标间相互作用,以及用于心血管事件的预测,具有相当重要的意义,如果在临床研究中注意收集这些信息,有助于形成新的临床发现。

 德国学者的一项研究表明,入院时生长分化因子15(GDF-15)单次测定可显著增强急性冠脉事件注册(GRACE)评分的预测价值。论文于2011年12月23日在线发表于《欧洲心脏杂志》(Eur Heart J)。

  GRACE是一项经验证的非ST段抬高型急性冠脉综合征(NSTE-ACS)评分系统。此项研究共纳入1122例NSTE-ACS患者,并在其入院时确定了GRACE评分、GDF-15和N末端前B型利钠肽(NT- proBNP)。主要终点为6个月全因死亡率或非致死性心肌梗死(MI)。在推导人群(754例;66例出现主要终点)中制定统计算法,并将其应用于验证人群(368例;33例)。

  结果显示,在验证人群中,利用GDF-15对GRACE风险估计进行校正可使受试者工作特征曲线(AUC)下面积由0.79升高至 0.85(P<0.001)。鉴别力改善由鉴别力综合改善(IDI)0.055被加以证实。净31%的无事件患者被重新分类为低危,净27%的伴事件患者被重新分类为高危,从而使净分类改善达到0.58(P=0.002)。将NT-proBNP添加至GRACE评分中可产生相似的鉴别力和重新分类改善。将GDF-15添加至包含NT-proBNP和GRACE的模型中可进一步改善模型效能。

  链接:  Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome

相关研究:

MMP-2与梗死面积/左室功能障碍相关

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=10187, encodeId=5b011018e07, content=多谢您啦., beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 18:12:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655640, encodeId=0dd61655640e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Aug 14 09:24:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819087, encodeId=4f22181908e3a, content=<a href='/topic/show?id=de2d99226e2' target=_blank style='color:#2F92EE;'>#非ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99226, encryptionId=de2d99226e2, topicName=非ST段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Nov 08 19:24:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430314, encodeId=5cb21430314b9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624316, encodeId=a331162431603, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626451, encodeId=9493162645119, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=)]
    2014-06-29 lidage

    多谢您啦.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=10187, encodeId=5b011018e07, content=多谢您啦., beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 18:12:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655640, encodeId=0dd61655640e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Aug 14 09:24:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819087, encodeId=4f22181908e3a, content=<a href='/topic/show?id=de2d99226e2' target=_blank style='color:#2F92EE;'>#非ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99226, encryptionId=de2d99226e2, topicName=非ST段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Nov 08 19:24:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430314, encodeId=5cb21430314b9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624316, encodeId=a331162431603, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626451, encodeId=9493162645119, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=)]
    2012-08-14 shanyongle
  3. [GetPortalCommentsPageByObjectIdResponse(id=10187, encodeId=5b011018e07, content=多谢您啦., beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 18:12:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655640, encodeId=0dd61655640e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Aug 14 09:24:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819087, encodeId=4f22181908e3a, content=<a href='/topic/show?id=de2d99226e2' target=_blank style='color:#2F92EE;'>#非ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99226, encryptionId=de2d99226e2, topicName=非ST段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Nov 08 19:24:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430314, encodeId=5cb21430314b9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624316, encodeId=a331162431603, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626451, encodeId=9493162645119, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=)]
    2012-11-08 lxg951
  4. [GetPortalCommentsPageByObjectIdResponse(id=10187, encodeId=5b011018e07, content=多谢您啦., beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 18:12:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655640, encodeId=0dd61655640e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Aug 14 09:24:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819087, encodeId=4f22181908e3a, content=<a href='/topic/show?id=de2d99226e2' target=_blank style='color:#2F92EE;'>#非ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99226, encryptionId=de2d99226e2, topicName=非ST段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Nov 08 19:24:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430314, encodeId=5cb21430314b9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624316, encodeId=a331162431603, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626451, encodeId=9493162645119, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=10187, encodeId=5b011018e07, content=多谢您啦., beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 18:12:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655640, encodeId=0dd61655640e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Aug 14 09:24:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819087, encodeId=4f22181908e3a, content=<a href='/topic/show?id=de2d99226e2' target=_blank style='color:#2F92EE;'>#非ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99226, encryptionId=de2d99226e2, topicName=非ST段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Nov 08 19:24:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430314, encodeId=5cb21430314b9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624316, encodeId=a331162431603, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626451, encodeId=9493162645119, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=)]
    2011-12-31 hyf035
  6. [GetPortalCommentsPageByObjectIdResponse(id=10187, encodeId=5b011018e07, content=多谢您啦., beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 18:12:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655640, encodeId=0dd61655640e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Aug 14 09:24:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819087, encodeId=4f22181908e3a, content=<a href='/topic/show?id=de2d99226e2' target=_blank style='color:#2F92EE;'>#非ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99226, encryptionId=de2d99226e2, topicName=非ST段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Nov 08 19:24:00 CST 2012, time=2012-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430314, encodeId=5cb21430314b9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624316, encodeId=a331162431603, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626451, encodeId=9493162645119, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 31 11:24:00 CST 2011, time=2011-12-31, status=1, ipAttribution=)]

相关资讯

新英格兰:氯吡格雷和阿司匹林在急性冠脉综合征(ACS)中的应用剂量比较

氯吡格雷和阿司匹林在急性冠脉综合征中的剂量比较研究 Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes  背景 氯吡格雷和阿司匹林被广泛用于有急性冠脉综合征(ACS)的病人,以及接受经皮冠脉介入(PCI)治疗者。然而,目前尚未制定这两种药物给药剂量的循证指南。   方法 我们在1项2×2析因设计中,将

RESONSE:护士组织协调的预防项目对急性冠脉综合征后心血管风险的影响

    摘要:心血管疾病的二级预防指南与实际执行情况还有很大差距。在RESONSE研究中,我们定量分析了基于医院的护士组织协调的预防项目对于确诊的冠状动脉疾病患者发生远期并发症的影响。    方法:RESONSE是一项荷兰进行的11个医疗中心参与的随机临床试验。纳入患者年龄从18至80岁不等,在入选前8周内因急性冠脉临床事件住院。患者被随

柳叶刀:CYP2C19和ABCB1多态性对三种格雷类药物用于急性冠脉综合征的比较

MedSci独家:这是本周刚刚发表在The Lancet上两篇文章,是两篇大规模临床试验的结果,比较替卡格雷,氯吡格雷和普拉格雷在急性冠脉综合征中差异。虽然三个属于同一类药物,但对于不同患者可能作用并不相同。主要表现在几个方面:(1)该药靶向基因的多态性,可能直接影响到药物作用靶点;(2)药物代谢相关基因的多态性变化,这可能直接影响到该药物在血浆中的浓度。 文章一: 在 PLATO试验中,口服

替格瑞洛治疗急性冠脉综合征获准

    7月20日,美国食品和药物管理局(FDA)批准了抗凝药替格瑞洛(ticagrelor ,商品名Brilinta)用于减少急性冠脉综合征(ACS)病人的心血管死亡和心脏病发作。   ACS包括一组心脏缺血症状,其原因包括不稳定型心绞痛或心脏病发作。Brilinta通过预防体内新的血栓形成来维持血流,有助于减少再次心血管事件的危险。   研究人员已对Brilinta联